<DOC>
	<DOCNO>NCT02867306</DOCNO>
	<brief_summary>The primary purpose study evaluate effect ASP1707 twice daily pharmacokinetics weekly oral methotrexate ( MTX ) . This study also evaluate effect MTX multiple-dose pharmacokinetics ASP1707 , well safety tolerability coadministration ASP1707 MTX patient rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics ASP1707 Methotrexate Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Patients check clinic Day -1 remain clinic exit procedure perform morning Day 10 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Female patient must either : Be nonchildbearing potential : postmenopausal ( define least 2 year last regular menstrual cycle ) prior screen folliclestimulating hormone ( FSH ) ≥ 30 IU/mL , document surgically sterile Or , childbearing potential , Agree try become pregnant study 28 day 5 halflives , whichever longer , final study drug administration ; negative urine pregnancy test screening ; , heterosexually active , agree consistently use 2 form highly effective birth control ( least one must barrier method ) start screen throughout study period 28 day 5 halflives , whichever longer , final study drug administration . Male patient female spouse/partner childbearing potential must use highly effective form contraception consist 2 form birth control ( 1 must barrier method ) start screen continue throughout study period 60 day final study drug administration . Female patient must agree breastfeed start screen throughout study period , 28 day 5 halflives , whichever longer , final study drug administration . Female patient must donate ovum start screen throughout study period , 28 day 5 halflives , whichever longer , final study drug administration . Male patient must donate sperm start screen throughout study period , 60 day final study drug administration . Patient agree participate another interventional study treatment . Patient body mass index ( BMI ) ≤ 35 kg/m2 , inclusive , must weigh least 50 kg screening . Patient must clinical diagnosis RA accord 2010 criteria American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) least 6 month prior screen . Patient meet ACR 1991 revise criterion RA Global Functional Status I II . Patient must concomitant MTX stable 10 25 mg/week dose ≥ 28 day prior day 1 throughout study . Patient medication ( exclude MTX ) treatment RA time screen must able discontinue medication 28 day 5 halflives ( whichever longer ) first study drug dose : Hydroxychloroquine , cyclosporine , leflunomide sulfasalazine Patient use nonsteroidal antiinflammatory drug ( NSAIDs ) , COX2 inhibitor , folic acid , low dose opioids , hormone replacement therapy ( HRT ) , corticosteroid ( prednisone equivalent ≤ 5 mg/day ) treatment RA may allow study . These medication must stable ≥ 28 day prior screen patient remain regimen throughout study . Occasional acetaminophen use ( less 2 g/day ) may allow . Patient use conventional biologic diseasemodifying antirheumatic drug ( DMARDs ) use treat RA may allow study . These medication must stable 4 week prior study remain stable study . Prior approval use must obtain sponsor . Patient previous history clinically significant systemic disease might confound result study pose additional risk administer study drug ( ) patient . This may include , limited , history drug food allergy , uncompensated heart failure , uncontrolled diabetes mellitus , severe hepatic failure , severe pulmonary disease , history mental disease . Patient history malignancy past 5 year , except adequatelytreated nonmelanoma skin cancer adequatelytreatedinsitu cervical cancer . Patient positive serology test hepatitis B surface antigen ( HbsAg ) hepatitis C virus ( HCV ) antibody human immunodeficiency virus ( HIV ) 1+2 antibody . Patient receive breast cancer resistance protein ( BCRP ) transporter inhibitor substrates , exception MTX , within 28 day 5 halflives , whichever longer , prior day 1 . Patient liver enzyme test abnormality , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) total bilirubin &gt; 2 time upper limit normal ( ULN ) . Patient recent history ( within last 6 month ) drug alcohol abuse ( define Investigator ) positive urine screen alcohol drug abuse/illegal drug screen checkin . Patient participate previous clinical study treatment ASP1707 . Patient receive investigational agent within 28 day 5 halflives , whichever longer , prior day 1 . Patient significant blood loss , donate 1 unit ( 450 mL ) blood , , receive transfusion blood blood product within 60 day donate plasma within 7 day prior day 1 . Patient employee Astellas group vendor involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>methotrexate ( MTX )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ASP1707</keyword>
	<keyword>Rheumatoid Arthritis ( RA )</keyword>
</DOC>